NCT00479349View on ClinicalTrials.gov

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Alzheimer Disease
Interventions
DRUG

SAM-531

Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.

Trial Locations (1)

170-0003

Tokyo

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00479349 - Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 | Biotech Hunter | Biotech Hunter